Oracle's AI Order Book Meets a Harder Question at the Credit Window
Published on 11/19/2026 at 13:00 | Editorial boerse-global.deOracle's credit profile has become the more telling gauge of its AI buildout than any product launch. Media reports flagged a rise in premiums for insuring against an Oracle default, a signal that debt investors are watching the gap between signed contracts and actual cash.
That gap is the crux. Oracle enters fiscal 2026 with roughly $664 billion in contracted performance obligations not yet booked as revenue, largely from AI customers such as OpenAI. The backlog gives the data-center expansion a tangible foundation, yet it says nothing about when those contracts convert into sales — or when sales turn into free cash flow.
The cash trajectory explains the market's unease. Free cash flow stood at $11.8 billion in fiscal 2024 and swung to minus $23.7 billion in fiscal 2026. A negative figure is not the same as absent demand, but it does mean nothing is left over after capital spending. For investors, the question is how long Oracle must carry the buildout before orders show up in higher cash generation.
Two $10 Billion Raises, One 7.8% Coupon
In November the company tapped capital markets on two fronts, issuing $10 billion of stock and $10 billion of bonds. The notes carried an average coupon of about 7.8%. S&P had already cut Oracle's credit rating to BBB- in July.
The raise proved Oracle can access funding. It also made plain that the expansion is not purely a revenue story for shareholders. Fresh equity spreads the claim on future earnings across more shares, while bond interest accrues regardless of how quickly Oracle delivers on contracted work.
Should investors sell immediately? Or is it worth buying Oracle?
Clinical and Project Tools Move From Demo to Deployment
On the product side, Oracle keeps pushing AI into everyday workflows. Microsoft and Oracle said in an Azure blog post that Copilot and Foundry assistants will connect to the Oracle AI Database, letting them run approved database queries and pull predefined reports without data leaving the database. An Oracle plug-in for Excel is already available.
Oracle also unveiled Life Sciences AI Agents for monitoring clinical trial portfolios and for planning and running studies, initially open to early adopters, with proposed actions requiring human review and approval. Extensions to Primavera Cloud — an AI help assistant, a reusable risk library and revamped collaborative scheduling — are generally available, though the assistant only in selected regions.
A concrete customer win adds weight: Shore Medical Center and Shore Physicians Group chose Oracle Health's AI-driven electronic health record, planning to merge the hospital's and the physician group's clinical systems. The agreement was struck in February, with Shore targeting completion by December 2027. Separately, the U.S. Department of Veterans Affairs and the U.S. Department of War have participated in the Oracle Health Information Network since November 5, per a November 13 announcement.
Guarantees and a Lapsing Microsoft Deal
The counterweight sits in the financial commitments behind the infrastructure. Bloomberg reported Monday that Applied Digital is demanding multibillion-dollar financial guarantees from Oracle before signing new leases, citing concerns over potential cost obligations tied to the power grid. That demand is not an agreed obligation — but should Oracle assume such guarantees, the risks of the buildout would rise.
Demand signals are mixed as well. Reuters reported on November 6 that Microsoft is letting its agreement to rent AI compute at Oracle lapse after a contract renewal failed to materialize. Oracle countered that demand for OCI AI infrastructure, including older graphics processors, remains strong. The company's demand statement argues against a blanket weakness thesis; the expiring contract still counsels separating broad demand from the durability of individual customer relationships.
What the Next Quarters Must Prove
Consensus expects positive free cash flow only in the second half of fiscal 2028 — an expectation, not a promised turning point. Oracle also plans to bring Cerebras model execution to OCI in calendar 2027, alongside Shore's expected December 2027 go-live.
The confirmation that matters is not another product headline. It is visible progress from offering to actual use — without an outsized expansion of financial obligations. That ratio, more than the size of the backlog, is the yardstick for Oracle's next AI steps.
Ad
Oracle Stock: New Analysis - 19 November
Fresh Oracle information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
